CAR T-cells for colorectal cancer immunotherapy: Ready to go?
CAR T cells
clinical data
colorectal cancer
immunotherapies
tumor microenvironement
tumor mutational burden
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
06
2022
accepted:
14
10
2022
entrez:
2
12
2022
pubmed:
3
12
2022
medline:
6
12
2022
Statut:
epublish
Résumé
Chimeric antigen receptor (CAR) T-cells represent a new genetically engineered cell-based immunotherapy tool against cancer. The use of CAR T-cells has revolutionized the therapeutic approach for hematological malignancies. Unfortunately, there is a long way to go before this treatment can be developed for solid tumors, including colorectal cancer. CAR T-cell therapy for colorectal cancer is still in its early stages, and clinical data are scarce. Major limitations of this therapy include high toxicity, relapses, and an impermeable tumor microenvironment for CAR T-cell therapy in colorectal cancer. In this review, we summarize current knowledge, highlight challenges, and discuss perspectives regarding CAR T-cell therapy in colorectal cancer.
Identifiants
pubmed: 36458008
doi: 10.3389/fimmu.2022.978195
pmc: PMC9705989
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
978195Informations de copyright
Copyright © 2022 Ghazi, El Ghanmi, Kandoussi, Ghouzlani and Badou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Mol Sci. 2021 Oct 29;22(21):
pubmed: 34769211
J Immunol. 2009 Jun 1;182(11):6744-52
pubmed: 19454669
Clin Cancer Res. 2012 May 1;18(9):2478-89
pubmed: 22371455
Sci Rep. 2021 Nov 2;11(1):21504
pubmed: 34728682
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Cancers (Basel). 2019 Jan 07;11(1):
pubmed: 30621018
Clin Cancer Res. 2012 Dec 1;18(23):6436-45
pubmed: 23032741
J Leukoc Biol. 2019 Feb;105(2):243-255
pubmed: 30387907
Front Immunol. 2021 Jul 09;12:679425
pubmed: 34305910
Nat Immunol. 2017 Feb 15;18(3):255-262
pubmed: 28198830
J Clin Invest. 2016 Oct 3;126(10):3814-3826
pubmed: 27571406
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Mol Ther. 2017 May 3;25(5):1248-1258
pubmed: 28366766
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Front Immunol. 2020 Sep 30;11:565631
pubmed: 33101285
Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):607-20
pubmed: 23856888
Int J Cancer. 2020 May 1;146(9):2531-2538
pubmed: 31396956
Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S2-5
pubmed: 23085599
Cancer Gene Ther. 2000 Feb;7(2):284-91
pubmed: 10770638
Biochem Cell Biol. 2019 Apr;97(2):85-90
pubmed: 30273495
Sci Transl Med. 2019 Jul 17;11(501):
pubmed: 31316010
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
J Immunother Cancer. 2018 May 14;6(1):35
pubmed: 29754585
Oncoimmunology. 2020 Nov 25;9(1):1846926
pubmed: 33312759
J Mol Biol. 2007 Jul 6;370(2):220-30
pubmed: 17512947
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Cancers (Basel). 2019 Dec 23;12(1):
pubmed: 31878090
Cells. 2020 Feb 27;9(3):
pubmed: 32121014
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14827-32
pubmed: 8962140
Hum Pathol. 2005 Feb;36(2):170-9
pubmed: 15754294
Expert Rev Anticancer Ther. 2018 Oct;18(10):991-1006
pubmed: 30019590
Cell Death Dis. 2021 Nov 27;12(12):1109
pubmed: 34839348
Front Immunol. 2021 Oct 13;12:762341
pubmed: 34721435
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Immunotherapy. 2019 Feb;11(3):201-213
pubmed: 30730277
Cancer Cell. 2018 Dec 10;34(6):1012-1026.e3
pubmed: 30537506
Cancer Gene Ther. 2020 May;27(5):341-355
pubmed: 31155611
Cancer Lett. 2015 Aug 28;365(1):23-9
pubmed: 25980820
Cancer Cell. 2015 Apr 13;27(4):437-8
pubmed: 25873170
World J Gastroenterol. 2016 Aug 14;22(30):6876-89
pubmed: 27570424
J Cancer. 2021 Sep 13;12(22):6629-6639
pubmed: 34659553
Nat Biotechnol. 2019 Sep;37(9):1049-1058
pubmed: 31332324
Cancer Cell. 2012 Dec 11;22(6):699-701
pubmed: 23238008
Nature. 2012 Feb 08;482(7385):400-4
pubmed: 22318521
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Invest New Drugs. 2020 Dec;38(6):1888-1898
pubmed: 32488569
Mol Ther. 2011 Mar;19(3):620-6
pubmed: 21157437
Vaccines (Basel). 2020 Jul 10;8(3):
pubmed: 32664247
Expert Rev Precis Med Drug Dev. 2021;6(2):117-129
pubmed: 34027103
Mol Med Rep. 2019 Sep;20(3):2355-2364
pubmed: 31322180
World J Gastroenterol. 2020 Apr 7;26(13):1394-1426
pubmed: 32308343
Mol Ther. 2010 Feb;18(2):413-20
pubmed: 19773745
Br J Cancer. 2005 May 9;92(9):1746-53
pubmed: 15856045
J Cancer. 2021 Jan 21;12(6):1804-1814
pubmed: 33613769
Onco Targets Ther. 2018 Aug 21;11:5047-5057
pubmed: 30174443
Curr Opin Immunol. 2014 Apr;27:8-15
pubmed: 24487185
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
Front Oncol. 2020 Aug 26;10:1594
pubmed: 32984022
Clin Cancer Res. 2018 Jun 1;24(11):2473-2481
pubmed: 29386217
Cancer Lett. 2014 Aug 28;351(1):151-61
pubmed: 24880079
Cancer Res. 2016 Jul 15;76(14):4090-9
pubmed: 27287716
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13255-60
pubmed: 11687624
Front Immunol. 2022 Jun 01;13:883694
pubmed: 35720311
Oncoimmunology. 2016 Sep 2;5(10):e1227897
pubmed: 27853651
Nat Genet. 2013 Jan;45(1):98-103
pubmed: 23202126
Front Immunol. 2019 Oct 11;10:2250
pubmed: 31681259
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8
pubmed: 2513569
Cancer. 2019 Dec 1;125(23):4139-4147
pubmed: 31433498
Biomark Med. 2015;9(4):363-75
pubmed: 25808440
Oncotarget. 2017 Feb 21;8(8):13545-13559
pubmed: 28088790
Cancer Lett. 2018 Oct 1;433:165-175
pubmed: 29981429
Curr Opin Immunol. 2018 Apr;51:55-61
pubmed: 29525346
J Natl Compr Canc Netw. 2022 Feb;20(2):167-192
pubmed: 35130500
J Hematol Oncol. 2018 Apr 23;11(1):58
pubmed: 29685162
Am J Pathol. 2001 Jul;159(1):297-304
pubmed: 11438476
Front Oncol. 2021 Feb 02;10:608609
pubmed: 33604291
Front Oncol. 2020 Jun 24;10:885
pubmed: 32670871
Mol Ther Oncolytics. 2021 Feb 24;20:556-568
pubmed: 33738341
J Oncol. 2021 Jul 6;2021:9918116
pubmed: 34326875
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
Clin Cancer Res. 2012 Dec 15;18(24):6758-70
pubmed: 23032743
Cancers (Basel). 2019 Feb 06;11(2):
pubmed: 30736355
Front Immunol. 2021 Oct 28;12:765097
pubmed: 34777381
Best Pract Res Clin Haematol. 2018 Jun;31(2):176-183
pubmed: 29909918
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359
pubmed: 33724754
J Immunother Cancer. 2019 Jul 15;7(1):183
pubmed: 31307554
Mol Cell. 2019 Nov 7;76(3):359-370
pubmed: 31668929
J Clin Oncol. 2018 Oct 20;36(30):2978-2979
pubmed: 30179566
J Thorac Dis. 2018 Aug;10(8):4689-4693
pubmed: 30233840
Mol Cancer. 2011 Aug 31;10:106
pubmed: 21880146
Cancer Immunol Res. 2016 Nov;4(11):959-967
pubmed: 27671167
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
J Hematol Oncol. 2017 Jan 5;10(1):4
pubmed: 28057014
Front Immunol. 2020 Feb 26;11:326
pubmed: 32194561
J Surg Res. 2022 Apr;272:37-50
pubmed: 34929499
Hepatology. 2009 Nov;50(5):1453-63
pubmed: 19676131
Nature. 2014 Aug 21;512(7514):324-7
pubmed: 25043048
Clin Cancer Res. 2021 Sep 1;27(17):4680-4684
pubmed: 33846198
Cancer Res. 2015 Aug 1;75(15):3043-53
pubmed: 26054597
Oncoimmunology. 2018 May 7;7(7):e1440169
pubmed: 29900044
Biochem J. 2009 Dec 10;424(3):449-58
pubmed: 19747165
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cancer Metastasis Rev. 2020 Sep;39(3):969-987
pubmed: 32507912
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Front Immunol. 2022 May 11;13:795164
pubmed: 35634281
Mol Ther. 2019 Oct 2;27(10):1825-1835
pubmed: 31331813
Front Oncol. 2018 Aug 03;8:237
pubmed: 30123774
Mol Cancer. 2017 Mar 14;16(1):63
pubmed: 28288645
Front Oncol. 2020 Jul 28;10:1243
pubmed: 32850376
Front Oncol. 2020 May 06;10:697
pubmed: 32435621
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Hum Gene Ther. 2019 Apr;30(4):402-412
pubmed: 30693795
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Int J Mol Sci. 2017 Jun 21;18(6):
pubmed: 28635639
Nat Med. 2013 Jun;19(6):747-52
pubmed: 23644516
Biochem J. 2012 Mar 1;442(2):293-302
pubmed: 21999204
BMJ Open. 2017 Nov 12;7(11):e017075
pubmed: 29133316
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
J Exp Clin Cancer Res. 2022 Mar 31;41(1):119
pubmed: 35361234
Blood. 2014 Jul 17;124(3):453-62
pubmed: 24891321
Front Pharmacol. 2021 Nov 01;12:724306
pubmed: 34790117
Front Oncol. 2021 Jan 06;10:574860
pubmed: 33489881
Expert Opin Investig Drugs. 2019 Jan;28(1):29-38
pubmed: 30513002
Ann N Y Acad Sci. 2000;915:136-43
pubmed: 11193569
Cells. 2020 Apr 03;9(4):
pubmed: 32260097
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
J Clin Oncol. 2013 Nov 10;31(32):e439-42
pubmed: 24043743
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Int J Mol Sci. 2019 Apr 17;20(8):
pubmed: 30999624
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Front Oncol. 2020 May 27;10:849
pubmed: 32670869
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Front Immunol. 2020 Sep 24;11:531491
pubmed: 33072086
Cancer Res. 2012 Mar 1;72(5):1081-91
pubmed: 22237626
Cancer Immunol Res. 2018 May;6(5):509-516
pubmed: 29615399
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
J Exp Med. 2014 Oct 20;211(11):2231-48
pubmed: 25245761
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Gastroenterology. 2008 May;134(5):1296-310
pubmed: 18471507
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Cancer Cell Int. 2019 Aug 7;19:209
pubmed: 31406485
Semin Oncol. 2015 Aug;42(4):663-71
pubmed: 26320069
Int J Cancer. 1995 Apr 10;61(2):272-9
pubmed: 7705958
Cancer Immunol Res. 2018 Jan;6(1):14-24
pubmed: 29097422
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5002-7
pubmed: 15047891
J Biomed Sci. 2017 Apr 4;24(1):26
pubmed: 28376884
Front Oncol. 2021 Aug 06;11:720501
pubmed: 34422667
Front Oncol. 2020 Oct 16;10:588134
pubmed: 33178614
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Hematol Oncol. 2022 Jul 16;15(1):95
pubmed: 35842707
J Immunother Cancer. 2017 Mar 21;5:22
pubmed: 28344808
Front Biosci (Landmark Ed). 2020 Jun 1;25(9):1765-1786
pubmed: 32472757
J Immunol Res. 2018 Oct 15;2018:4263520
pubmed: 30410941
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
Nat Rev Clin Oncol. 2021 Feb;18(2):63
pubmed: 33349691
Cancers (Basel). 2022 Mar 09;14(6):
pubmed: 35326556
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32843493
Am J Pathol. 1999 Jun;154(6):1805-13
pubmed: 10362805
Biochem Biophys Res Commun. 2013 May 3;434(2):352-6
pubmed: 23558291
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Cancer Lett. 2021 Feb 1;498:201-209
pubmed: 33129958
Cancer Cell. 2017 Mar 13;31(3):311-325
pubmed: 28292435
Cancer. 2007 Aug 15;110(4):926-35
pubmed: 17580361
Nature. 2012 Jul 5;487(7405):64-9
pubmed: 22763440
Ther Adv Med Oncol. 2015 May;7(3):153-69
pubmed: 26673925
Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436
pubmed: 28660319
Front Cell Dev Biol. 2020 Oct 15;8:569219
pubmed: 33178688
Cancer Med. 2012 Aug;1(1):5-16
pubmed: 23342249
Front Immunol. 2018 Mar 12;9:476
pubmed: 29662484
J Int Med Res. 2012;40(6):2109-16
pubmed: 23321167
J Immunol. 2008 May 15;180(10):7028-38
pubmed: 18453625
Curr Cancer Drug Targets. 2018;18(9):857-868
pubmed: 29295696
Mol Ther. 2020 Nov 4;28(11):2320-2339
pubmed: 32979309
Nat Cancer. 2022 May;3(5):581-594
pubmed: 35314826
Int J Mol Sci. 2019 Mar 14;20(6):
pubmed: 30875739
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
Am J Cancer Res. 2019 May 01;9(5):945-958
pubmed: 31218103
Clin Dev Immunol. 2012;2012:238924
pubmed: 22481963
Sci Rep. 2017 Oct 30;7(1):14366
pubmed: 29085043
Front Oncol. 2021 Jun 23;11:657545
pubmed: 34249693
Crit Rev Oncol Hematol. 2022 Jan;169:103538
pubmed: 34801700
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Lett. 2015 Oct 28;367(2):103-7
pubmed: 26188281
Cancer Immunol Res. 2015 Jun;3(6):575-82
pubmed: 26041808
Biomedicines. 2021 Apr 07;9(4):
pubmed: 33917081
Curr Opin Virol. 2016 Dec;21:9-15
pubmed: 27379906
Mol Cancer Res. 2008 Feb;6(2):186-93
pubmed: 18245228
Immunother Adv. 2021 Aug 13;1(1):ltab018
pubmed: 34604863
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
Nat Biotechnol. 2019 Dec;37(12):1425-1434
pubmed: 31160723
Front Immunol. 2020 May 15;11:940
pubmed: 32499786
J Immunother. 2019 Feb/Mar;42(2):33-42
pubmed: 30586347
Mol Ther Oncolytics. 2020 May 04;17:421-430
pubmed: 32462079
Cancer Med. 2019 Aug;8(10):4753-4765
pubmed: 31237116
J Pathol Clin Res. 2021 Nov;7(6):577-589
pubmed: 34363325